• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HCV 替换和 IL28B 多态性对聚乙二醇干扰素联合利巴韦林治疗的影响。

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.

机构信息

Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN, Hiroshima, Japan.

出版信息

Gut. 2011 Feb;60(2):261-7. doi: 10.1136/gut.2010.223495. Epub 2010 Nov 10.

DOI:10.1136/gut.2010.223495
PMID:21068134
Abstract

BACKGROUND AND AIMS

A number of recent studies have shown that human polymorphisms near the IL28B type III interferon (IFNλ) gene influence the response to peg-interferon plus ribavirin combination therapy for infection with chronic hepatitis C virus (HCV). Viral polymorphisms, including substitutions within the HCV core and NS5A proteins, have also been shown to influence treatment outcome, but it is not known whether these factors act independently of the IL28B polymorphism or if they reflect the same or a different underlying mechanism. Multiple logistic regression was used to determine whether host and viral polymorphisms independently predict sustained virological response (SVR).

METHODS

Two single nucleotide polymorphisms were genotyped in the IL28B locus (rs12979860 and rs8099917) from 817 patients with chronic HCV infection, and substitutions at amino acids 70 and 91 of the HCV core protein and within the NS5A interferon sensitivity-determining region (ISDR) were analysed.

RESULTS

It was found that independent predictors of an SVR included IL28B rs12979860 CC genotype (OR=4.98; p=4.00E-08), core amino acid 70 substitutions (OR=0.53; p=0.016), age and baseline viral load. For non-virological response, the IL28B rs12979860 CT/TT genotype (OR=0.23; p=1.96E-8) and age were independent predictors. IL28B rs12979860 genotype (p=1.4E-8), core amino acid 70 substitutions (p=0.0013), ISDR substitutions (p=0.0019), baseline viral load, γ-glutamyltranspeptidase, alanine aminotransferase and platelet count were independent predictors for change in viral load by week 4 of treatment.

CONCLUSIONS

IL28B polymorphisms and HCV core amino acid 70 substitutions contribute independently to an SVR to peg-interferon plus ribavirin combination therapy.

摘要

背景与目的

近期多项研究表明,人类白细胞介素 28B 型 III 干扰素(IFNλ)基因附近的多态性影响聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎病毒(HCV)感染的应答。病毒多态性,包括 HCV 核心和 NS5A 蛋白内的替换,也已被证明影响治疗结果,但尚不清楚这些因素是否独立于 IL28B 多态性起作用,或者它们是否反映了相同或不同的潜在机制。多变量逻辑回归用于确定宿主和病毒多态性是否独立预测持续病毒学应答(SVR)。

方法

对 817 例慢性 HCV 感染患者的 IL28B 基因座(rs12979860 和 rs8099917)进行了两种单核苷酸多态性基因分型,并分析了 HCV 核心蛋白氨基酸 70 和 91 的替换以及 NS5A 干扰素敏感性决定区(ISDR)内的替换。

结果

发现 SVR 的独立预测因素包括 IL28B rs12979860 CC 基因型(OR=4.98;p=4.00E-08)、核心氨基酸 70 替换(OR=0.53;p=0.016)、年龄和基线病毒载量。对于非病毒学应答,IL28B rs12979860 CT/TT 基因型(OR=0.23;p=1.96E-8)和年龄是独立的预测因素。IL28B rs12979860 基因型(p=1.4E-8)、核心氨基酸 70 替换(p=0.0013)、ISDR 替换(p=0.0019)、基线病毒载量、γ-谷氨酰转肽酶、丙氨酸氨基转移酶和血小板计数是治疗第 4 周时病毒载量变化的独立预测因素。

结论

IL28B 多态性和 HCV 核心氨基酸 70 替换独立于聚乙二醇干扰素联合利巴韦林治疗的 SVR。

相似文献

1
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.HCV 替换和 IL28B 多态性对聚乙二醇干扰素联合利巴韦林治疗的影响。
Gut. 2011 Feb;60(2):261-7. doi: 10.1136/gut.2010.223495. Epub 2010 Nov 10.
2
Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.IL28B基因变异rs12979860和rs8099917对慢性丙型肝炎4型患者联合治疗病毒学应答的强大预测作用
Liver Int. 2014 Jul;34(6):890-5. doi: 10.1111/liv.12321. Epub 2013 Oct 14.
3
Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.白细胞介素 28B 与丙型肝炎病毒核心区和 NS5A 区突变与聚乙二醇干扰素和利巴韦林治疗反应的关系。
Liver Int. 2011 Oct;31(9):1359-65. doi: 10.1111/j.1478-3231.2011.02571.x. Epub 2011 Jun 23.
4
Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.IL28B 基因(rs8099917、rs12979860)多态性与巴基斯坦丙型肝炎病毒基因型 3 患者对聚乙二醇干扰素治疗的病毒学应答。
Int J Infect Dis. 2015 Jan;30:91-7. doi: 10.1016/j.ijid.2014.09.021. Epub 2014 Nov 20.
5
IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.IL28B 多态性决定了接受聚乙二醇干扰素/利巴韦林治疗慢性丙型肝炎 1 型患者的早期病毒动力学和治疗结果。
J Viral Hepat. 2011 Jul;18(7):e325-31. doi: 10.1111/j.1365-2893.2010.01425.x. Epub 2011 Jan 13.
6
Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.荟萃分析:IL28B 多态性可预测聚乙二醇干扰素-α和利巴韦林治疗的 HCV 患者的持续病毒应答。
Aliment Pharmacol Ther. 2012 Jul;36(2):91-103. doi: 10.1111/j.1365-2036.2012.05131.x. Epub 2012 May 16.
7
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.采用 IL28B 基因多态性和病毒因素对聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎的反应进行预处理预测。
J Hepatol. 2011 Mar;54(3):439-48. doi: 10.1016/j.jhep.2010.07.037. Epub 2010 Sep 19.
8
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.白细胞介素28B基因多态性和病毒因素有助于识别从24周聚乙二醇化干扰素联合利巴韦林治疗中获益的丙型肝炎病毒1型患者。
Antivir Ther. 2012;17(3):477-84. doi: 10.3851/IMP2026. Epub 2011 Dec 20.
9
Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.聚乙二醇干扰素 α-2b/利巴韦林联合治疗时,用干扰素-β/利巴韦林进行导入治疗可能会改变 IL28B 微基因型慢性丙型肝炎患者的早期丙型肝炎病毒动力学。
J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.
10
Prevalence of rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C.rs4803217单核苷酸多态性的患病率与慢性丙型肝炎的临床病程
World J Gastroenterol. 2017 Jun 7;23(21):3815-3824. doi: 10.3748/wjg.v23.i21.3815.

引用本文的文献

1
Personalized medicine and nutrition in hepatology for preventing chronic liver disease in Mexico.墨西哥肝病学中预防慢性肝病的个性化医疗与营养
Front Nutr. 2024 May 9;11:1379364. doi: 10.3389/fnut.2024.1379364. eCollection 2024.
2
Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha.聚乙二醇干扰素-α抗病毒治疗中干扰素-λ 3 和 4 多态性增加持续病毒学应答并调节固有免疫。
Front Cell Infect Microbiol. 2021 Jul 7;11:656393. doi: 10.3389/fcimb.2021.656393. eCollection 2021.
3
Association of Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy.
基因型与聚乙二醇干扰素和利巴韦林联合治疗慢性丙型肝炎患者肝脂肪变性的关系。
Int J Med Sci. 2017 Sep 4;14(11):1088-1093. doi: 10.7150/ijms.20171. eCollection 2017.
4
High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan.台湾一个多民族地区丙型肝炎病毒感染者中有利的白细胞介素-28B rs8099917 多态性的高频出现及其临床意义。
Kaohsiung J Med Sci. 2017 Oct;33(10):510-515. doi: 10.1016/j.kjms.2017.06.005. Epub 2017 Jul 1.
5
Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy.丙型肝炎病毒1b基因型野生型和密码子70突变型核心毒株对聚乙二醇化干扰素-α和利巴韦林治疗的动力学反应。
Virol J. 2015 Dec 18;12:220. doi: 10.1186/s12985-015-0451-9.
6
Prevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of Nepal.尼泊尔三个地区注射吸毒者中艾滋病毒、乙型和丙型肝炎感染率以及丙型肝炎病毒基因型和两个IL28B单核苷酸多态性的评估
PLoS One. 2015 Aug 11;10(8):e0134455. doi: 10.1371/journal.pone.0134455. eCollection 2015.
7
Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.白细胞介素28B基因多态性作为慢性丙型肝炎持续病毒学应答的预测指标:系统评价与荟萃分析
Pharmacogenomics J. 2016 Feb;16(1):18-29. doi: 10.1038/tpj.2015.28. Epub 2015 Apr 28.
8
Clinical utility of pharmacogenomics in the management of hepatitis C.药物基因组学在丙型肝炎管理中的临床应用
Pharmgenomics Pers Med. 2014 Oct 20;7:339-47. doi: 10.2147/PGPM.S52624. eCollection 2014.
9
Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients.初治的基因1b型慢性丙型肝炎患者接受基于替拉瑞韦的三联疗法24周治疗反应的预测因素。
Gastroenterol Res Pract. 2014;2014:549709. doi: 10.1155/2014/549709. Epub 2014 Aug 14.
10
Quantitation of substitutions at amino acid 70 in hepatitis C virus genotype 1b.丙型肝炎病毒1b基因型中第70位氨基酸替代的定量分析。
Virol J. 2014 Aug 15;11:148. doi: 10.1186/1743-422X-11-148.